Advances in local and ablative treatment of oligometastasis in prostate cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 10, Issue 4, 2014, Pages 308-321

  Yao, Henry H ^a   Hong, Matthew K ^a   Corcoran, Niall M ^a,b   Siva, Shankar ^c   Foroudi, Farshad ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Australian Prostate Cancer Research   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Metastasectomy; Oligometastasis; Prostate cancer; Stereotactic ablative radiotherapy

Indexed keywords

ABLATION THERAPY; ANDROGEN DEPRIVATION THERAPY; ANEMIA; CANCER RADIOTHERAPY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; FATIGUE; FLUSHING; FOLLOW UP; FRACTURE; HEMATURIA; HUMAN; INSULIN RESISTANCE; LIBIDO DISORDER; METASTASIS; METASTASIS RESECTION; OLIGOMETASTASIS; OSTEOPOROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; RECURRENT DISEASE; REVIEW; SYNCHRONOUS OLIGOMETASTASIS; SYSTEMATIC REVIEW; URINE INCONTINENCE; BONE NEOPLASMS; MALE; NEOPLASM METASTASIS; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOSURGERY; SECONDARY;

BONE NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOSURGERY;

EID: 84909638965     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12256     Document Type: Review

References (75)

1. Niibe Y, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med 2012; 2012: 261096.
2. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13: 8-10.
3. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010; 40: 107-111.
4. Singh D, Yi WS, Brasacchio RA etal. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 2004; 58: 3-10.
5. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-695.
6. Minn AJ, Gupta GP, Siegel PM etal. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524.
7. Norton L, Massague J. Is cancer a disease of self-seeding? Nat Med 2006; 12: 875-878.
8. Man YG, Gardner WA. Bad seeds produce bad crops: a single stage-process of prostate tumor invasion. Int J Biol Sci 2008; 4: 246-258.
9. Mottet N, Bellmunt J, Bolla M etal. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-583.
10. Pagliarulo V, Bracarda S, Eisenberger MA etal. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012; 61: 11-25.
11. Heidenreich A, Bastian PJ, Bellmunt J etal. Guidelines on prostate cancer. European Association of Urology, updated 11 Aug 2013, 2013. [Cited 11 Aug 2013.] Available from URL: http://www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf
12. Kirby R, Challacombe B, Dasgupta P, Fitzpatrick JM. Prostate cancer treatment: the times they are a "changin". BJU Int 2012; 110: 1408-1411.
13. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169: 164-169.
14. Picchio M, Briganti A, Fanti S etal. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011; 59: 51-60.
15. Ernst DS, Hanson J, Venner PM. Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J Urol 1991; 146: 372-376.
16. Soloway MS, Hardeman SW, Hickey D etal. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202.
17. Furuya Y, Akakura K, Akimoto S, Inomiya H, Ito H. Pattern of progression and survival in hormonally treated metastatic prostate cancer. Int J Urol 1999; 6: 240-244.
18. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013; 31: 1384-1390.
19. Chao DH, Higgins JP, Brooks JD. Biochemical remission after resection of prostate cancer lung metastasis. Urology 2004; 63: 584-585.
20. Sweets T, Bracken RB, Geisler EJ, Warnick R. Intracranial treatment for solitary prostatic adenocarcinoma brain metastasis is curative. Urology 2009; 73 (681): e7-9.
21. Shin YS, Doo AR, Kim MK, Jeong YB, Kim HJ. First case of peritoneal seeding of prostate cancer during robot-assisted laparoscopic radical prostatectomy. Can J Urol 2012; 19: 6303-6305.
22. Lee ST, Lawrentschuk N, Scott AM. PET in prostate and bladder tumors. Semin Nucl Med 2012; 42: 231-246.
23. Badakhshi H, Grun A, Stromberger C, Budach V, Boehmer D. Oligometastases: the new paradigm and options for radiotherapy : a critical review. Strahlenther Onkol 2013; 189: 357-362.
24. Yossepowitch O, Bianco FJ Jr, Eggener SE, Eastham JA, Scher HI, Scardino PT. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol 2007; 51: 940-947, discussion 47-8.
25. Pepe P, Fraggetta F, Tornabene F, Nicolosi M, Aragona F. Solitary lung metastasis after radical prostatectomy in presence of undetectable PSA. Arch Ital Urol Androl 2012; 84: 208-210.
26. Kwon SY, Jung HS, Lee JG, Choi SH, Kwon TG, Kim TH. Solitary testicular metastasis of prostate cancer mimicking primary testicular cancer. Korean J Urol 2011; 52: 718-720.
27. Kim SO, Choi YD, Jung SI etal. Prostate cancer with solitary metastases to the bilateral testis. Yonsei Med J 2011; 52: 362-364.
28. Smaali C, Gobet F, Dugardin F, Pfister C. Testicular metastasis of prostatic cancer. Urology 2010; 75: 249-250.
29. Janssen S, Bernhards J, Anastasiadis AG, Bruns F. Solitary testicular metastasis from prostate cancer: a rare case of isolated recurrence after radical prostatectomy. Anticancer Res 2010; 30: 1747-1749.
30. Goto T, Maeshima A, Oyamada Y, Kato R. Solitary pulmonary metastasis from prostate sarcomatoid cancer. World J Surg Oncol 2010; 8: 101.
31. Pruthi RS, Hubbard JS, Kouba E, Wallen E. Androgen-independent prostate cancer treated with resection of the solitary metastatic site. Urol Int 2007; 79: 371-373.
32. Metzdorf MM, Schmidt JD. Isolated prostate cancer recurrence presenting as pelvic mass nine years after radical retropubic prostatectomy. Urology 2007; 70 (1007): e17-18.
33. Comperat E, Azzouzi AR, Chartier-Kastler E etal. Late recurrence of a prostatic adenocarcinoma as a solitary splenic metastasis. Urol Int 2007; 78: 86-88.
34. Menchini-Fabris F, Giannarini G, Pomara G etal. Testicular metastasis as isolated recurrence after radical prostatectomy. A first case. Int J Impot Res 2007; 19: 108-109.
35. Smith CP, Sharma A, Ayala G, Cagle P, Kadmon D. Solitary pulmonary metastasis from prostate cancer. J Urol 1999; 162: 2102.
36. Hofland CA, Bagg MD. An isolated pulmonary metastasis in prostate cancer. Mil Med 2000; 165: 973-974.
37. Bromberg WD, Gaylis FD, Bauer KD, Schaeffer AJ. Isolated pulmonary metastases from carcinoma of the prostate: a case report and deoxyribonucleic acid analysis using flow cytometry. J Urol 1989; 141: 137-139.
38. Rockey KE, Graham TE. Prostate adenocarcinoma metastatic to the lung. Postgrad Med 1990; 87: 199-205, 208.
39. Friedel G, Hurtgen M, Penzenstadler M, Kyriss T, Toomes H. Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res 1999; 19: 1593-1596.
40. Going JJ, Brewin TB, Crompton GK, McLelland J. Soft tissue sarcoma: two cases of solitary lung metastasis more than 15 years after diagnosis. Clin Radiol 1986; 37: 579-581.
41. Kreisman H, Wolkove N, Finkelstein HS, Cohen C, Margolese R, Frank H. Breast cancer and thoracic metastases: review of 119 patients. Thorax 1983; 38: 175-179.
42. McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ. Lung resection for colorectal metastases. 10-year results. Arch Surg 1992; 127: 1403-1406.
43. Bubendorf L, Schopfer A, Wagner U etal. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 2000; 31: 578-583.
44. Schick U, Jorcano S, Nouet P etal. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 2013; 52: 1622-1628.
45. Tabata K, Niibe Y, Satoh T etal. Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer. Pulm Med 2012; 2012: 541656.
46. Rades D, Veninga T, Stalpers LJ etal. Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. J Clin Oncol 2007; 25: 50-56.
47. Berkovic P, De Meerleer G, Delrue L etal. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 2013; 11: 27-32.
48. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2012; 2: 215.
49. Kao J, Chen CT, Tong CC etal. Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol 2014; 9: 145-153.
50. Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol 2013; 31: 455-460.
51. Jereczek-Fossa BA, Piperno G, Ronchi S etal. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol 2012; 18: 18.
52. Jereczek-Fossa BA, Beltramo G, Fariselli L etal. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 889-897.
53. Greco C, Zelefsky MJ, Lovelock M etal. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys 2011; 79: 1151-1157.
54. Casamassima F, Masi L, Menichelli C etal. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011; 97: 49-55.
55. Petrongari MG, Gomellini S, Arcangeli S etal. Stereotactic body radiation therapy for isolated nodal recurrences of prostate cancer. Anticancer Res 2011; 31: 1928-1929.
56. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 2007; 25: 947-952.
57. Lo SS, Fakiris AJ, Chang EL etal. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 2010; 7: 44-54.
58. Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol 2010; 5: 1091-1099.
59. Garcia-Barros M, Paris F, Cordon-Cardo C etal. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-1159.
60. Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell 2005; 8: 89-91.
61. Lee Y, Auh SL, Wang Y etal. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009; 114: 589-595.
62. Finkelstein SE, Timmerman R, McBride WH etal. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011; 2011: 439752.
63. Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 2012; 84: 879-880.
64. Wolbarst AB, Chin LM, Svensson GK. Optimization of radiation therapy: integral-response of a model biological system. Int J Radiat Oncol Biol Phys 1982; 8: 1761-1769.
65. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163-169.
66. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176.
67. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008; 14: 317-322.
68. The International Registry of Lung Metastases Writing Committee, Pastorino U, Buyse M et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997; 113: 37-49.
69. Morris EJ, Forman D, Thomas JD etal. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010; 97: 1110-1118.
70. Jereczek-Fossa B, Piperno G, Ronchi S etal. Stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Radiother Oncol 2012; 103: S17.
71. Bhandari MS, Crook J, Hussain M. Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 2005; 23: 8212-8218.
72. Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int 2013; 111: 543-548.
73. Eastern Cooperative Oncology Group. ECOG common toxicity criteria. Eastern Cooperative Oncology Group, updated 15 June 2007, 2002. [Cited 11 Aug 2013.] Available from URL: http://www.ecog.org/general/common_tox.html
74. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
75. Alongi F, Schipani S, Gajate AM etal. [11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. Tumori 2010; 96: 613-617.